ERBB2 c.2241A>C ;(p.K747N)

Variant ID: 17-37880197-A-C

NM_004448.2(ERBB2):c.2241A>C;(p.K747N)

This variant was identified in 2 publications

View GRCh38 version.




Publications:


Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight.

Cell Reports. Medicine
Hurst, Carolyn D CD; Cheng, Guo G; Platt, Fiona M FM; Castro, Mauro A A MAA; Marzouka, Nour-Al-Dain S NS; Eriksson, Pontus P; Black, Emma V I EVI; Alder, Olivia O; Lawson, Andrew R J ARJ; Lindskrog, Sia V SV; Burns, Julie E JE; Jain, Sunjay S; Roulson, Jo-An JA; Brown, Joanne C JC; Koster, Jan J; Robertson, A Gordon AG; Martincorena, Inigo I; Dyrskjøt, Lars L; Höglund, Mattias M; Knowles, Margaret A MA
Publication Date: 2021-12-21

Variant appearance in text: ERBB2: K747N
PubMed Link: 35028613
Variant Present in the following documents:
  • mmc1.pdf
  • mmc7.pdf
View BVdb publication page



mTOR Signaling and SREBP Activity Increase FADS2 Expression and Can Activate Sapienate Biosynthesis.

Cell Reports
Triki, Mouna M; Rinaldi, Gianmarco G; Planque, Melanie M; Broekaert, Dorien D; Winkelkotte, Alina M AM; Maier, Carina R CR; Janaki Raman, Sudha S; Vandekeere, Anke A; Van Elsen, Joke J; Orth, Martin F MF; Grünewald, Thomas G P TGP; Schulze, Almut A; Fendt, Sarah-Maria SM
Publication Date: 2020-06-23

Variant appearance in text: ERBB2: K747N
PubMed Link: 32579932
Variant Present in the following documents:
  • mmc5.xlsx, sheet 3
View BVdb publication page